Intus Bio Strengthens Industry Leading Microbiome Platform with Acquisition of Pattern Genomics
Transaction adds advanced machine learning technologies for microbiome analysis
FARMINGTON, Conn., June 28, 2023 /PRNewswire-PRWeb/ -- Intus Biosciences, LLC(Intus Bio), creators of the industry-leading Titan-1™ microbiome research and testing platform, has announced the strategic acquisition of Pattern Genomics, a developer of advanced genomic analysis software tools. This transaction was made possible with the support of Connecticut Innovations, an investor in both companies.
The development enhances Intus Bio's portfolio of end-to-end data-driven solutions for microbiome discovery and understanding. The company has a long history of collaboration with Pattern Genomics and a deep appreciation of the technology being acquired.
The Intus Bio Titan-1™ platform combines patented assays and next-generation proprietary analysis tools for an unprecedented ability to generate high accuracy, high-resolution strain-level data on a high-throughput basis. The integration of Pattern Genomics' technology brings additional machine learning tools for biomarker discovery and patient stratification, across extensive datasets and populations.
As part of the transaction, Pattern Genomics Founder and President, Daniel Fasulo has joined Intus Bio as Head of IT and Bioinformatics.
"We're grateful for the support of Connecticut Innovations, as we add the impressive technology of Pattern Genomics to Intus Bio. Together, we have an unmatched ability to produce and analyze high-resolution bacterial data at scale, creating incredible opportunities across every aspect of healthcare" said Paul Denslow, Intus Bio's CEO. "We are also very pleased to have Dan join the Intus Bio leadership team, as he's a fantastic addition we already know well."
"After nearly 11 years of developing a portfolio of bioinformatics technologies at Pattern Genomics, I am thrilled with this transaction and to join the Intus Bio team," said Daniel Fasulo, President of Pattern Genomics. "There is no better home for Pattern than Intus Bio, as they bring microbiome technologies into practical medical and pharmaceutical applications."
"Intus Bio has acquired a powerful asset in Pattern, adding to their already impressive and groundbreaking Titan-1™ assay and analysis platform," said Dan Wagner, Senior Managing Director of Investments at Connecticut Innovations. "The exciting combination of these technologies only increases their significant potential to impact the healthcare industry. We look forward to being part of Intus Bio's future success."
About Intus Biosciences, LLC:
Intus Bio has developed world-leading technology to identify bacteria and deliver answers about the microbiome with unprecedented detail, accuracy, and scale. Its patented and validated Titan-1TM platform combines high-throughput assay and analysis technology to generate strain-level information. The company provides advanced research and commercial services across global pharmaceutical, diagnostic, and testing industries; is active in health, agricultural, and environmental fields; and continually develops new partnerships, technologies, and applications.
About Pattern Genomics, LLC:
Founded in 2011, Pattern Genomics has developed sophisticated bioinformatics tools that seek to uncover patterns and key biomarkers from massive genomic data sets. The technology, when combined with next-generation sequencing, powers efficient, data-driven processes that can be applied to a broad range of health and diagnostic problems.
About Connecticut Innovations:
Connecticut Innovations (CI) is Connecticut's strategic venture capital arm and the leading source of financing and ongoing support for Connecticut's innovative, growing companies. CI provides venture capital and strategic support for early-stage technology companies, financial support for innovation and collaboration, and connections to its well-established network of partners and professionals.
To learn more or to partner with Intus Biosciences, visit intusbio.com.
Media Contact
Elizabeth Chabe, Intus Biosciences, +1 207 907-6962, [email protected]
SOURCE Intus Biosciences
Share this article